Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company focusing on human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in collaboration with its U.S. partner 10X Health, aims to expand their joint product pipeline and strengthen their international collaboration in innovative genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the body. As an integral part of key metabolic pathways, it can significantly influence the function and processing of various biological molecules, including vitamins and neurotransmitters. While many commercially available tests analyze only a limited number of relevant genes, MGT Plus covers a total of 27 genes, providing a more comprehensive picture of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, stated, "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health."
The global direct-to-consumer testing market is experiencing strong growth: in 2025, the market size had already reached approximately $4.7 billion and is projected to grow to more than $16.0 billion by 2033. The genetic testing sector is developing particularly dynamically; with a share of over 40 percent, it already represents the largest segment of the market today. North America plays a leading role in this sector, accounting for around 50 percent of global market volume in 2025. This growth is driven by increasing interest in personalized health information, prevention, and individually tailored health services.
Novogenia's expanded MGT Plus test is positioned to capitalize on this trend by offering a more detailed genetic analysis that can inform personalized prevention and health strategies. The company's partnership with 10X Health is expected to facilitate broader access to this advanced testing in the U.S. market, potentially enhancing the ability of healthcare providers to offer tailored recommendations based on genetic insights.
The launch of MGT Plus represents a significant step forward in Novogenia's mission to integrate genetic analysis into routine health management. By providing a more comprehensive assessment of methylation-related pathways, the test aims to empower individuals and healthcare professionals with actionable information for optimizing health and longevity.
For more information about Novogenia and its products, visit https://novogenia.com/novogenia-ag.
